Free Trial

Ligand Pharmaceuticals (LGND) Competitors

Ligand Pharmaceuticals logo
$135.83 +3.00 (+2.26%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$135.91 +0.08 (+0.06%)
As of 07/25/2025 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LGND vs. ADMA, ANIP, EXAS, MDGL, HALO, RGEN, IONS, ALKS, FOLD, and BCRX

Should you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), Exact Sciences (EXAS), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Repligen (RGEN), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), and BioCryst Pharmaceuticals (BCRX). These companies are all part of the "medical" sector.

Ligand Pharmaceuticals vs. Its Competitors

Ligand Pharmaceuticals (NASDAQ:LGND) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$167.13M15.68-$4.03M-$7.12-19.08
ADMA Biologics$426.45M10.08$197.67M$0.8521.19

In the previous week, ADMA Biologics had 3 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 8 mentions for ADMA Biologics and 5 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.90 beat ADMA Biologics' score of 0.85 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ligand Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ADMA Biologics
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ligand Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

ADMA Biologics has a net margin of 45.01% compared to Ligand Pharmaceuticals' net margin of -73.07%. ADMA Biologics' return on equity of 47.16% beat Ligand Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ligand Pharmaceuticals-73.07% -7.83% -6.92%
ADMA Biologics 45.01%47.16%30.51%

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ligand Pharmaceuticals currently has a consensus price target of $147.17, suggesting a potential upside of 8.35%. ADMA Biologics has a consensus price target of $27.67, suggesting a potential upside of 53.62%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ligand Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
ADMA Biologics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

Summary

ADMA Biologics beats Ligand Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Ligand Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LGND vs. The Competition

MetricLigand PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.62B$3.05B$5.70B$9.50B
Dividend YieldN/A2.37%4.58%4.00%
P/E RatioN/A21.3228.3920.07
Price / Sales15.68270.06427.4498.54
Price / Cash84.5342.7636.2258.56
Price / Book3.098.378.675.88
Net Income-$4.03M-$55.19M$3.25B$258.89M
7 Day Performance-2.35%5.86%4.30%3.70%
1 Month Performance17.41%17.29%10.57%11.71%
1 Year Performance26.78%4.39%35.68%17.98%

Ligand Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LGND
Ligand Pharmaceuticals
3.5351 of 5 stars
$135.83
+2.3%
$147.17
+8.3%
+28.1%$2.62B$167.13M0.0080
ADMA
ADMA Biologics
3.6008 of 5 stars
$17.04
-3.1%
$27.67
+62.4%
+37.7%$4.07B$426.45M20.06530News Coverage
ANIP
ANI Pharmaceuticals
3.8571 of 5 stars
$67.58
-0.7%
$78.88
+16.7%
+8.8%$1.46B$614.38M-53.20600Positive News
EXAS
Exact Sciences
4.7431 of 5 stars
$52.01
-0.4%
$70.50
+35.6%
+0.3%$9.82B$2.76B-9.457,000News Coverage
Positive News
MDGL
Madrigal Pharmaceuticals
4.3127 of 5 stars
$338.14
-3.0%
$420.63
+24.4%
+5.3%$7.51B$180.13M-18.7390News Coverage
Insider Trade
HALO
Halozyme Therapeutics
4.8504 of 5 stars
$57.38
-0.7%
$62.70
+9.3%
+4.1%$7.05B$1.02B15.22390Positive News
RGEN
Repligen
4.6366 of 5 stars
$121.01
-2.4%
$170.75
+41.1%
-8.0%$6.83B$634.44M-270.151,778Upcoming Earnings
Analyst Upgrade
IONS
Ionis Pharmaceuticals
4.5354 of 5 stars
$42.04
-0.3%
$57.13
+35.9%
-18.5%$6.68B$705M-14.051,069News Coverage
Upcoming Earnings
ALKS
Alkermes
4.7817 of 5 stars
$29.44
+0.3%
$40.92
+39.0%
-6.8%$4.85B$1.56B14.081,800Upcoming Earnings
FOLD
Amicus Therapeutics
4.0511 of 5 stars
$6.16
-2.1%
$16.22
+163.6%
-40.9%$1.90B$528.29M-68.38480News Coverage
Upcoming Earnings
BCRX
BioCryst Pharmaceuticals
4.4364 of 5 stars
$8.69
-0.1%
$16.70
+92.2%
+13.2%$1.81B$450.71M-33.25530Analyst Upgrade

Related Companies and Tools


This page (NASDAQ:LGND) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners